Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Compounds (3)
- Butyrylcholinesterase (2)
- Chelating (2)
- Chelators (2)
- Cocaine (2)
-
- Hydrolysis (2)
- Immobilized (2)
- Method (2)
- Tumor (2)
- Aluminum (1)
- Analogs (1)
- Antibiotics (1)
- Antibiotics, Antineoplastic (1)
- Antineoplastic (1)
- Antioxidant (1)
- Berry (1)
- Breathing zone (1)
- Camptothecin (1)
- Camptothecins (1)
- Cancer chemotherapy (1)
- Cell Line (1)
- Cell Line, Tumor (1)
- Cell Survival (1)
- Compositions (1)
- Controlled drug release (1)
- Decorporation (1)
- Delayed-Action Preparations (1)
- Dermal exposure (1)
- Drug (1)
- Drug Carriers (1)
Articles 1 - 13 of 13
Full-Text Articles in Medicine and Health Sciences
Effect Of Duration And Amplitude Of Direct Current When Lidocaine Is Delivered By Iontophoresis, Susan A. Saliba, Courtney L. Teeter-Heyl, Patrick O. Mckeon, Christopher D. Ingeroll, Ethan N. Saliba
Effect Of Duration And Amplitude Of Direct Current When Lidocaine Is Delivered By Iontophoresis, Susan A. Saliba, Courtney L. Teeter-Heyl, Patrick O. Mckeon, Christopher D. Ingeroll, Ethan N. Saliba
Physical Therapy Faculty Publications
Dosage for the galvanic stimulation for iontophoresis varies. Clinicians manipulate the duration or the amplitude of the current, but it is not known which is more effective. We compared the anesthetic effect of lidocaine HCL (2%) by manipulating the current parameters on 21 healthy volunteers (age: 21.2 ± 4.2, height 170.7 ± 10.2 cm, mass 82.1 ± 19.2 kg). Three conditions were administered in a random order using a Phoresor II® with 2 mL, 2% lidocaine HCL in an iontophoresis electrode. (1) HASD (40 mA*min): High amplitude (4 mA), short duration (10 min); (2) LALD (40 mA.min): …
Liposomal, Ring-Opened Camptothecins With Prolonged, Site-Specific Delivery Of Active Drug To Solid Tumors, Bradley D. Anderson, Vijay Joguparthi, Tiang-Xiang Xiang
Liposomal, Ring-Opened Camptothecins With Prolonged, Site-Specific Delivery Of Active Drug To Solid Tumors, Bradley D. Anderson, Vijay Joguparthi, Tiang-Xiang Xiang
Pharmaceutical Sciences Faculty Patents
A method for preparing a stable dispersion of a camptothecin, camptothecin prodrug, or analog thereof for administration to a patient in need thereof includes preparing a solution of the camptothecin, wherein the solution has a pH which places substantially an entirety of that camptothecin in a carboxylate form. The camptothecin may be a neutral camptothecin. The solution is next loaded into a liposome including at least one lipid, which may be a phospholipid. An intraliposomal pH is maintained which preserves substantially an entirety of the camptothecin in the carboxylate form. The liposomal dispersion is administered to an individual in need …
Removing Aluminum From Solution Using Chelating Compounds And Immobilized Tethered Chelators, Robert A. Yokel, Wesley R. Harris, Christopher D. Spilling, Chang-Guo Zhan
Removing Aluminum From Solution Using Chelating Compounds And Immobilized Tethered Chelators, Robert A. Yokel, Wesley R. Harris, Christopher D. Spilling, Chang-Guo Zhan
Pharmaceutical Sciences Faculty Patents
Methods are described for removing aluminum from a solution using novel di- and tripodal compounds as chelators.
Nanoparticulate Formulations Of Mithramycin Analogs For Enhanced Cytotoxicity, Daniel Scott, Jürgen Rohr, Younsoo Bae
Nanoparticulate Formulations Of Mithramycin Analogs For Enhanced Cytotoxicity, Daniel Scott, Jürgen Rohr, Younsoo Bae
Pharmaceutical Sciences Faculty Publications
Mithramycin (MTM), a natural product of soil bacteria from the Streptomyces genus, displays potent anticancer activity but has been limited clinically by severe side effects and toxicities. Engineering of the MTM biosynthetic pathway has produced the 3-side-chain-modified analogs MTM SK (SK) and MTM SDK (SDK), which have exhibited increased anticancer activity and improved therapeutic index. However, these analogs still suffer from low bioavailability, short plasma retention time, and low tumor accumulation. In an effort to aid with these shortcomings, two nanoparticulate formulations, poly(ethylene glycol)-poly(aspartate hydrazide) self-assembled and cross-linked micelles, were investigated with regard to the ability to load and pH …
Methods And Pharmaceutical Compositions For Decorporation Of Radioactive Compounds, Michael Jay, Russell J. Mumper
Methods And Pharmaceutical Compositions For Decorporation Of Radioactive Compounds, Michael Jay, Russell J. Mumper
Pharmaceutical Sciences Faculty Patents
A composition for removing a radioactive element or compound such as systemic transuranic compounds, from mammals comprises a pharmaceutical carrier and a decorporation agent comprising ester and amide derivatives of DTPA. A method of treating a mammal to remove systemic compounds utilizing the DTPA derivatives is also disclosed.
Degradable Cross-Linked Nanoassemblies As Drug Carriers For Heat Shock Protein 90 Inhibitor 17-N-Allylamino-17-Demethoxy-Geldanamycin, Andrei G. Ponta, Shanjida Akter, Younsoo Bae
Degradable Cross-Linked Nanoassemblies As Drug Carriers For Heat Shock Protein 90 Inhibitor 17-N-Allylamino-17-Demethoxy-Geldanamycin, Andrei G. Ponta, Shanjida Akter, Younsoo Bae
Pharmaceutical Sciences Faculty Publications
Cross-linked nanoassemblies (CNAs) with a degradable core were prepared for sustained release of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), a potent inhibitor of heat shock protein 90 (HSP90). The particle size of CNAs ranged between 100 and 250 nm, which changed depending on the cross-linking yields and drug entrapment method. CNAs with a 1% cross-linking yield entrapped 17-AAG in aqueous solutions, yet degraded in 3 hrs. CNAs entrapped 5.2 weight% of 17-AAG as the cross-linking yield increased to 10%, retaining more than 80% of particles for 24 hrs. CNAs with drugs entrapped after the cross-linking reactions were 100 nm and remained stable in both …
Histone Deacetylase Inhibitors And Mithramycin A Impact A Similar Neuroprotective Pathway At A Crossroad Between Cancer And Neurodegeneration, Sama F. Sleiman, Jill Berlin, Manuela Basso, Saravanan S. Karuppagounder, Jürgen Rohr, Rajiv R. Ratan
Histone Deacetylase Inhibitors And Mithramycin A Impact A Similar Neuroprotective Pathway At A Crossroad Between Cancer And Neurodegeneration, Sama F. Sleiman, Jill Berlin, Manuela Basso, Saravanan S. Karuppagounder, Jürgen Rohr, Rajiv R. Ratan
Pharmaceutical Sciences Faculty Publications
Mithramycin A (MTM) and histone deacetylase inhibitors (HDACi) are effective therapeutic agents for cancer and neurodegenerative diseases. MTM is a FDA approved aureolic acid-type antibiotic that binds to GC-rich DNA sequences and interferes with Sp1 transcription factor binding to its target sites (GC box). HDACi, on the other hand, modulate the activity of class I and II histone deacetylases. They mediate their protective function, in part, by regulating the acetylation status of histones or transcription factors, including Sp1, and in turn chromatin accessibility to the transcriptional machinery. Because these two classes of structurally and functionally diverse compounds mediate similar therapeutic …
Camptothecin Analogs And Methods Of Preparation Thereof, Dennis P. Curran, David Bom, Thomas Burke
Camptothecin Analogs And Methods Of Preparation Thereof, Dennis P. Curran, David Bom, Thomas Burke
Pharmaceutical Sciences Faculty Patents
To read this abstract, please download this patent.
Berry Preparations And Extracts, Russell J. Mumper, Jin Dai, Vincent S. Gallicchio
Berry Preparations And Extracts, Russell J. Mumper, Jin Dai, Vincent S. Gallicchio
Pharmaceutical Sciences Faculty Patents
A method for deriving compositions having antioxidant and anti-inflammatory activity from berries is provided. The method results in a berry extract compositions having stable anthocyanin content. In one aspect, the method comprises exposing a berry to a solvent composition having a pH of from about 1 to about 4.5, and recovering a berry extract having a stabilized anthocyanin content. The berry may be a blackberry. A cryoprotectant may be added, to further stabilize the anthocyanin content. Compositions comprising the berry extract of the present invention, formulated for oral and/or topical administration, are provided also, including nutritional supplements, capsules, enteric-coated capsules, …
Chelating Compounds And Immobilized Tethered Chelators, Robert A. Yokel, Wesley R. Harris, Christopher D. Spilling, Chang-Guo Zhan
Chelating Compounds And Immobilized Tethered Chelators, Robert A. Yokel, Wesley R. Harris, Christopher D. Spilling, Chang-Guo Zhan
Pharmaceutical Sciences Faculty Patents
Novel di- and tripodal compounds useful as chelators, intermediates for their production and a method for treating an aqueous solution to remove trivalent metal ions are presented.
High-Activity Mutants Of Butyrylcholinesterase For Cocaine Hydrolysis And Method Of Generating The Same, Chang-Guo Zhan, Hoon Cho, Hsin-Hsiung Tai
High-Activity Mutants Of Butyrylcholinesterase For Cocaine Hydrolysis And Method Of Generating The Same, Chang-Guo Zhan, Hoon Cho, Hsin-Hsiung Tai
Pharmaceutical Sciences Faculty Patents
A novel computational method and generation of mutant butyrylcholinesterase for cocaine hydrolysis is provided. The method includes molecular modeling a possible BChE mutant and conducting molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations thereby providing a screening method of possible BChE mutants by predicting which mutant will lead to a more stable transition state for a rate determining step. Site-directed mutagenesis, protein expression, and protein activity is conducted for mutants determined computationally as being good candidates for possible BChE mutants, i.e., ones predicted to have higher catalytic efficiency as compared with wild-type BChE. In addition, mutants A199S/A328W/Y332G, A199S/F227A/A328W/Y332G, A199S/S287G/A328W/Y332G, …
Engineered Nanomaterials: Exposures, Hazards, And Risk Prevention, Robert A. Yokel, Robert C. Macphail
Engineered Nanomaterials: Exposures, Hazards, And Risk Prevention, Robert A. Yokel, Robert C. Macphail
Pharmaceutical Sciences Faculty Publications
Nanotechnology presents the possibility of revolutionizing many aspects of our lives. People in many settings (academic, small and large industrial, and the general public in industrialized nations) are either developing or using engineered nanomaterials (ENMs) or ENM-containing products. However, our understanding of the occupational, health and safety aspects of ENMs is still in its formative stage. A survey of the literature indicates the available information is incomplete, many of the early findings have not been independently verified, and some may have been over-interpreted. This review describes ENMs briefly, their application, the ENM workforce, the major routes of human exposure, some …
High Activity Mutants Of Butyrylcholinesterase For Cocaine Hydrolysis, Chang-Guo Zhan, Fang Zheng, Wenchao Yang
High Activity Mutants Of Butyrylcholinesterase For Cocaine Hydrolysis, Chang-Guo Zhan, Fang Zheng, Wenchao Yang
Pharmaceutical Sciences Faculty Patents
Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (−)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (−)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.